Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1972 Oct;51(10):2593–2596. doi: 10.1172/JCI107076

Studies on the Response of Patients with Classic Hemophilia to Transfusion with Concentrates of Antihemophilic Factor

A DIFFERENCE IN THE HALF-LIFE OF ANTIHEMOPHILIC FACTOR AS MEASURED BY PROCOAGULANT AND IMMUNOLOGIC TECHNIQUES

Bruce Bennett 1, Oscar D Ratnoff 1
PMCID: PMC332957  PMID: 4626847

Abstract

Antihemophilic factor (AHF, factor VIII) levels were measured by a standard coagulation method and by an immunologic technique before and after infusion of AHF concentrates into patients with classic hemophilia. After infusion of AHF concentrates, the half-life of the AHF procoagulant (i.e., clot-promoting) activity varied from 12 to 14 hr, whereas that of the antigen ranged from 24 to 40 hr. The half-life of the antigen was similar in patients with and without circulating anticoagulants to AHF. The data are compatible with the suggestion that the antigen may be carried on a precursor molecule which the patient with hemophilia produces but cannot convert to the functional clot-promoting agent. Other explanations of the observations are, however, recognized.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ADELSON E., RHEINGOLD J. J., PARKER O., STEINER M., KIRBY J. C. The survival of factor VIII (antihemophilic globulin) and factor IX (plasma thromboplastin component) in normal humans. J Clin Invest. 1963 Jul;42:1040–1047. doi: 10.1172/JCI104789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BIGGS R., DENSON K. W. THE FATE OF PROTHROMBIN AND FACTORS VIII, IX AND X TRANSFUSED TO PATIENTS DEFICIENT IN THESE FACTORS. Br J Haematol. 1963 Oct;9:532–547. doi: 10.1111/j.1365-2141.1963.tb05478.x. [DOI] [PubMed] [Google Scholar]
  3. Bennett B., Ratnoff O. D., Levin J. Immunologic studies in von Willebrand's disease. Evidence that the antihemophilic factor (AHF) produced after transfusions lacks an antigen associated with normal AHF and the inactive material produced by patients with classic hemophilia. J Clin Invest. 1972 Oct;51(10):2597–2601. doi: 10.1172/JCI107077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Pool J. G., Shannon A. E. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system. N Engl J Med. 1965 Dec 30;273(27):1443–1447. doi: 10.1056/NEJM196512302732701. [DOI] [PubMed] [Google Scholar]
  5. Stites D. P., Hershgold E. J., Perlman J. D., Fudenberg H. H. Factor 8 detection by hemagglutination inhibition: hemophilia A and von Willebrand's disease. Science. 1971 Jan 15;171(3967):196–197. doi: 10.1126/science.171.3967.196. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES